These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 21802840)

  • 1. Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts.
    Balyasnikova IV; Ferguson SD; Han Y; Liu F; Lesniak MS
    Cancer Lett; 2011 Nov; 310(2):148-59. PubMed ID: 21802840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCε-dependent downregulation of AKT and XIAP expressions.
    Kahana S; Finniss S; Cazacu S; Xiang C; Lee HK; Brodie S; Goldstein RS; Roitman V; Slavin S; Mikkelsen T; Brodie C
    Cell Signal; 2011 Aug; 23(8):1348-57. PubMed ID: 21440622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy.
    Gong X; Schwartz PH; Linskey ME; Bota DA
    Neurology; 2011 Mar; 76(13):1126-34. PubMed ID: 21346220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.
    Jane EP; Premkumar DR; Pollack IF
    Mol Cancer Ther; 2011 Jan; 10(1):198-208. PubMed ID: 21220502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
    Koschny R; Holland H; Sykora J; Haas TL; Sprick MR; Ganten TM; Krupp W; Bauer M; Ahnert P; Meixensberger J; Walczak H
    Clin Cancer Res; 2007 Jun; 13(11):3403-12. PubMed ID: 17545549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis.
    Seol DW
    Biochem Biophys Res Commun; 2011 Dec; 416(1-2):222-5. PubMed ID: 22120628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRAIL conjugated to nanoparticles exhibits increased anti-tumor activities in glioma cells and glioma stem cells in vitro and in vivo.
    Perlstein B; Finniss SA; Miller C; Okhrimenko H; Kazimirsky G; Cazacu S; Lee HK; Lemke N; Brodie S; Umansky F; Rempel SA; Rosenblum M; Mikklesen T; Margel S; Brodie C
    Neuro Oncol; 2013 Jan; 15(1):29-40. PubMed ID: 23144078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.
    Shanker A; Brooks AD; Tristan CA; Wine JW; Elliott PJ; Yagita H; Takeda K; Smyth MJ; Murphy WJ; Sayers TJ
    J Natl Cancer Inst; 2008 May; 100(9):649-62. PubMed ID: 18445820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
    Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
    Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbenoxolone enhances TRAIL-induced apoptosis through the upregulation of death receptor 5 and inhibition of gap junction intercellular communication in human glioma.
    Yulyana Y; Endaya BB; Ng WH; Guo CM; Hui KM; Lam PY; Ho IA
    Stem Cells Dev; 2013 Jul; 22(13):1870-82. PubMed ID: 23428290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis.
    Unterkircher T; Cristofanon S; Vellanki SH; Nonnenmacher L; Karpel-Massler G; Wirtz CR; Debatin KM; Fulda S
    Clin Cancer Res; 2011 Jun; 17(12):4019-30. PubMed ID: 21525171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma.
    Kim SM; Lim JY; Park SI; Jeong CH; Oh JH; Jeong M; Oh W; Park SH; Sung YC; Jeun SS
    Cancer Res; 2008 Dec; 68(23):9614-23. PubMed ID: 19047138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway.
    Chen KF; Yeh PY; Hsu C; Hsu CH; Lu YS; Hsieh HP; Chen PJ; Cheng AL
    J Biol Chem; 2009 Apr; 284(17):11121-33. PubMed ID: 19261616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells.
    Baritaki S; Suzuki E; Umezawa K; Spandidos DA; Berenson J; Daniels TR; Penichet ML; Jazirehi AR; Palladino M; Bonavida B
    J Immunol; 2008 May; 180(9):6199-210. PubMed ID: 18424742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal delivery of mesenchymal stem cells significantly extends survival of irradiated mice with experimental brain tumors.
    Balyasnikova IV; Prasol MS; Ferguson SD; Han Y; Ahmed AU; Gutova M; Tobias AL; Mustafi D; Rincón E; Zhang L; Aboody KS; Lesniak MS
    Mol Ther; 2014 Jan; 22(1):140-8. PubMed ID: 24002694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.
    Premkumar DR; Jane EP; Agostino NR; DiDomenico JD; Pollack IF
    Mol Carcinog; 2013 Feb; 52(2):118-33. PubMed ID: 22086447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition.
    Hallett WH; Ames E; Motarjemi M; Barao I; Shanker A; Tamang DL; Sayers TJ; Hudig D; Murphy WJ
    J Immunol; 2008 Jan; 180(1):163-70. PubMed ID: 18097016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathway.
    Luo P; Lin M; Li L; Yang B; He Q
    PLoS One; 2011; 6(11):e27298. PubMed ID: 22087283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma.
    Perez LE; Parquet N; Meads M; Anasetti C; Dalton W
    Eur J Haematol; 2010 Mar; 84(3):212-22. PubMed ID: 19922463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts.
    Nawrocki ST; Sweeney-Gotsch B; Takamori R; McConkey DJ
    Mol Cancer Ther; 2004 Jan; 3(1):59-70. PubMed ID: 14749476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.